Expression Pattern of Long Non-coding RNAs in Schizophrenic Patients

Safari, Mohammad; Komaki‬, Alireza; Arsang‐Jang, Shahram; Taheri, Mohammad; Ghafouri‐Fard, Soudeh

doi:10.1007/s10571-018-0640-3

Cited by 41 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have recently demonstrated downregulation of FAS-AS1, PVT1, and TUG1 in patients with schizophrenia compared with controls. Yet, expressions of GAS5, NEAT1, and OIP5-AS1 were similar between patients and controls (24). Chen et al have reported the effects of olanzapine treatment in suppression of expression of the NONHSAT089447 lncRNA.…”

Section: Lncrna Profile In Peripheral Bloodmentioning

confidence: 94%

A Review on the Expression Pattern of Non-coding RNAs in Patients With Schizophrenia: With a Special Focus on Peripheral Blood as a Source of Expression Analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Schizophrenia is a destructive neuropsychiatric disease with a median prevalence of 4.0 per 1,000 during the whole life. Genome-wide association studies have shown the role of copy number variants (generally deletions) and certain alleles of common single nucleotide polymorphisms in the pathogenesis of schizophrenia. This disorder predominantly follows the polygenic inheritance model. Schizophrenia has also been linked with various alterations in the transcript and protein content of the brain tissue. Recent studies indicate that alterations in non-coding RNAs (ncRNAs) signature underlie a proportion of this dysregulation. High throughput microarray investigations have demonstrated momentous alterations in the expression of long non-coding RNAs (lncRNA) and microRNAs (miRNAs) in the circulation or post-mortem brain tissues of patients with schizophrenia compared with control samples. While Gomafu, PINT, GAS5, TCONS_l2_00021339, IFNG-AS1, FAS-AS1, PVT1, and TUG1 are among down-regulated lncRNAs in schizophrenia, MEG3, THRIL, HOXA-AS2, Linc-ROR, SPRY4-IT1, UCA1, and MALAT1 have been up-regulated in these patients. Moreover, several miRNAs, such as miR-30e, miR-130b, hsa-miR-130b, miR-193a-3p, hsa-miR-193a-3p, hsa-miR-181b, hsa-miR-34a, hsa-miR-346, and hsa-miR-7 have been shown to be dysregulated in blood or brain samples of patients with schizophrenia. Dysregulation of these transcripts in schizophrenia not only provides insight into the pathogenic processes of this disorder, it also suggests these transcripts could serve as diagnostic markers for schizophrenia. In the present paper, we explore the changes in the expression of miRNAs and lncRNAs in patients with schizophrenia.

show abstract

Section: Lncrna Profile In Peripheral Bloodmentioning

confidence: 94%

A Review on the Expression Pattern of Non-coding RNAs in Patients With Schizophrenia: With a Special Focus on Peripheral Blood as a Source of Expression Analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cases were recruited from hospitals affiliated with Shahid Beheshti and Hamadan Universities of Medical Sciences. The fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-V) was applied in the diagnostic process 21,22 . The standard dose of Clozapine (301 mg/day to 600 mg/day) was used for treatment of patients.…”

Section: Methodsmentioning

confidence: 99%

Expression of NF-κB associated lncRNAs in schizophrenia

Safa

Badrlou

Arsang‐Jang

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

NF-κB signaling pathway has important roles in the regulation of growth and development of nervous system. This pathway has also been shown to participate in the pathogenesis of schizophrenia. Meanwhile, activity of NF-κB signaling pathway is regulated by several factors including non-coding RNAs (lncRNAs). In the current study, we evaluated expression of nine NF-κB-related lncRNAs namely DILC, ANRIL, PACER, CHAST, ADINR, DICER1-AS1, HNF1A-AS1, H19 and NKILA as well as two mRNA coding genes namely ATG5 and CEBPA in the peripheral blood of patients with schizophrenia compared with matched healthy subjects. Expressions of these genes were assessed by real time PCR technique. Expression of PACER was lower in patients with schizophrenia compared with controls (Posterior beta = − 0.684, P value = 0.049). On the other hand, expressions of CHAST, CEBPA, H19, HNF1A-AS1 and DICER1-AS1 were higher in patients compared with controls (Posterior beta = 0.39, P value = 0.005; Posterior beta = 0.844, P value < 0.0001; Posterior beta = 0.467, P value < 0.0001; Posterior beta = 1.107, P value = 0.005; Posterior beta = 0.176, P value = 0.044, respectively). We also appraised the diagnostic power of transcript quantities of CHAST, CEBPA, DICER1-AS1, H19 and HNF1A-AS1 in distinguishing between patients with schizophrenia and controls through depicting ROC curves. Based on the area under curve (AUC) values, CEBPA had the best diagnostic power (AUC = 0.948, P < 0.0001), followed by H19 (AUC = 0.815, P < 0.0001). Taken together, our study demonstrated dysregulation of NF-κB-related lncRNAs and genes in the peripheral blood of patients with schizophrenia and their potential as peripheral markers for this psychiatric condition.

show abstract

“…The overexpression of lncRNA THRIL in patients with inflammatory‐related diseases is reported by several studies . For example, it is reported that lncRNA THRIL is highly expressed in rheumatoid arthritis (RA) patients compared to healthy controls and discriminates RA patients from controls .…”

Section: Discussionmentioning

confidence: 99%

Up‐regulation of long non‐coding RNA THRIL in coronary heart disease: Prediction for disease risk, correlation with inflammation, coronary artery stenosis, and major adverse cardiovascular events

Shen

Zhou

2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractObjective: This study aimed to investigate the role of long non-coding RNA (lncRNA) THRIL in coronary heart disease (CHD) patients. Methods:A total of 420 patients who underwent coronary arteriography due to suspected symptoms of CHD were enrolled, in which 220 were diagnosed as CHD and 200 were set as control subjects. LncRNA THRIL in plasma samples of CHD patients

show abstract

Expression Pattern of Long Non-coding RNAs in Schizophrenic Patients

Cited by 41 publications

References 28 publications

A Review on the Expression Pattern of Non-coding RNAs in Patients With Schizophrenia: With a Special Focus on Peripheral Blood as a Source of Expression Analysis

A Review on the Expression Pattern of Non-coding RNAs in Patients With Schizophrenia: With a Special Focus on Peripheral Blood as a Source of Expression Analysis

Expression of NF-κB associated lncRNAs in schizophrenia

Up‐regulation of long non‐coding RNA THRIL in coronary heart disease: Prediction for disease risk, correlation with inflammation, coronary artery stenosis, and major adverse cardiovascular events

Contact Info

Product

Resources

About